NeelimaDenduluriMD, FASCO

Oncology • Arlington, VA

Assistant Professor, Medicine, Georgetown University School of Medicine

Join to view full profile

Dr. Denduluri is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Denduluri's full profile

Already have an account?

Office
1635 N George Mason Dr
Ste 170
Arlington, VA 22205
Phone+1 703-894-3800

Fax+1 703-528-0338
Is this information wrong?

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2003 - 2007
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1999 - 2002
LSU School of Medicine in ShreveportClass of 1999

Certifications & Licensure

VA State Medical License 1999 - 2024
DC State Medical License 2001 - 2013
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer Start of enrollment: 2006 Jan 01
Completed
Not Applicable
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer Start of enrollment: 2012 Apr 01
Terminated
Phase 2
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation Start of enrollment: 2012 Aug 01
Completed
Phase 2, Phase 3
Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer Start of enrollment: 2014 Dec 01
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Filipa Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christophe...> ;Nature Communications. 2024 Mar 27
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Filipa Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christophe...> ;Medrxiv. 2023 Dec 4
4 citations
AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers.
Maysa M Abu-Khalaf, K Alex Hodge, Christos Hatzis, Elisa Baldelli, Emna El Gazzah, Frances Valdes, William M Sikov, Monica M Mita, Neelima Denduluri, Rita Murphy, Dani...> ;NPJ Precision Oncology. 2023 Feb 16
7 citations
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phas...
Frankie A Holmes, Beverly Moy, Suzette Delaloge, Stephen K L Chia, Bent Ejlertsen, Janine Mansi, Hiroji Iwata, Michael Gnant, Marc Buyse, Carlos H Barrios, Tajana Silo...> ;European Journal of Cancer. 2023 May 1
1 citations
Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Tr...
Neelima Denduluri, Janet L Espirito, Michelle D Hackshaw, Chuck Wentworth, Tamy Recchia, Winghan J Kwong> ;Drugs - Real World Outcomes. 2023 Jun 1
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, P...> ;The New England journal of medicine.
Pembrolizumab for Early Triple-Negative Breast Cancer.
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Ka...> ;The New England journal of medicine.
17 citations
Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysi...
Miguel Martin, Roberto Hegg, Sung-Bae Kim, Michael Schenker, Daniela Grecea, Jose Angel Garcia-Saenz, Konstantinos Papazisis, QuChang Ouyang, Aleksandra Lacko, Berna O...> ;JAMA Oncology. 2022 Aug 1
43 citations
Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0
Sara M. Tolaney, Elizabeth Garrett-Mayer, Julia White, Victoria S. Blinder, Jared C. Foster, Laleh Amiri-Kordestani, E. Shelley Hwang, Judith M Bliss, Eileen Rakovitch...> ;Journal of Clinical Oncology. 2021 May 18
1 citations
BRCA1/2 mutations and risk-reducing bilateral salpingo-oophorectomy among Latinas: The UPTAKE study.
Filipa Lynce, Ilana Schlam, Xue Geng, Beth N. Peshkin, Sue Friedman, Julie Dutil, Zeina Nahleh, Claudia Campos, Charité Ricker, Patricia Vázquez Rodríguez, Neelima Den...> ;Journal of Genetic Counseling. 2021 Apr 1
45 citations
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update
Neelima Denduluri, Mark R. Somerfield, Mariana Chavez-MacGregor, Amy Comander, Zoneddy Dayao, Andrea Eisen, Rachel A. Freedman, Ragisha Gopalakrishnan, Stephanie L. Gr...> ;Journal of Clinical Oncology. 2021 Feb 20
119 citations
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
Arlene Chan, Beverly Moy, Janine Mansi, Bent Ejlertsen, Frankie A. Holmes, Stephen Chia, Hiroji Iwata, Michael Gnant, Sibylle Loibl, Carlos H. Barrios, Isil Somali, Sn...> ;Clinical Breast Cancer. 2021 Feb 1
299 citations
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
Larissa A. Korde, Mark R. Somerfield, Lisa A. Carey, Jennie R. Crews, Neelima Denduluri, E. Shelley Hwang, Seema A. Khan, Sibylle Loibl, Elizabeth A. Morris, Alejandra...> ;Journal of Clinical Oncology. 2021 Jan 28
44 citations
Systemic therapy for metastatic HER2-positive breast cancer.
Philip Bredin, Janice M. Walshe, Neelima Denduluri> ;Seminars in Oncology. 2020 Aug 18
Examining Cardiotoxicity With HER2 Therapies
Neelima Denduluri> ;JACC. Cardiooncology. 2020 Jun 1
6 citations
Relationship Between Hereditary Cancer Syndromes and Oncotype DX Recurrence Score.
Nicole Casasanta, Sarit T. Kipnis, Laura Linville, Shawn Lipinski, Alice R. Knoedler, Amy Marino, Allision McHenry, Tara Biagi, Elizabeth Stark, Richard Amdur, Neelima...> ;Clinical Breast Cancer. 2020 Apr 1
45 citations
Symptom burden among older breast cancer survivors: The Thinking and Living With Cancer (TLC) study
Jeanne S. Mandelblatt, Wanting Zhai, Jaeil Ahn, Brent J. Small, Tim A. Ahles, Judith E. Carroll, Neelima Denduluri, Asma Dilawari, Martine Extermann, Deena Graham, Art...> ;Cancer. 2020 Mar 15
6 citations
ASCO Clinical Practice Guideline Endorsements and Adaptations
Manish A. Shah, Thomas K. Oliver, Douglas E. Peterson, Kaitlin Einhaus, Bryan J. Schneider, Neelima Denduluri, Mariana Chavez-MacGregor> ;Journal of Clinical Oncology. 2020 Mar 10
897 citations
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi, Cristina Saura, Toshinari Yamashita, Yeonhee Park, Sung Bae Kim, Kenji Tamura, Fabrice Andre, Hiroji Iwata, Yoshinori Ito, Junji Tsurutani, Joohyuk Sohn, N...> ;The New England Journal of Medicine. 2020 Feb 13
36 citations
Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer
Jeffrey Crawford, Neelima Denduluri, Debra A. Patt, Xiaolong Jiao, Phuong Khanh Morrow, Jacob Garcia, Richard Barron, Gary H. Lyman> ;Supportive Care in Cancer. 2020 Feb 1
28 citations
Sleep disturbance and neurocognitive outcomes in older patients with breast cancer: Interaction with genotype
Judith E. Carroll, Brent J. Small, Danielle Tometich, Wanting Zhai, Xingtao Zhou, George Luta, Tim A. Ahles, Andrew J. Saykin, Kelly N.H. Nudelman, Jonathan D. Clapp, ...> ;Cancer. 2019 Dec 15
4 citations
When to Add Additional Anti-HER2 Therapy to Adjuvant Trastuzumab.
Alexandra S Zimmer, Neelima Denduluri> ;Current Oncology Reports. 2019 Nov 28
3 citations
Critical Aspects of a Sustainable Clinical Research Program in the Community-Based Oncology Practice.
Jennifer L. Ersek, Stephanie L. Graff, Francis P. Arena, Neelima Denduluri, Edward S. Kim> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2019 May 17
18 citations
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
Stephen Chia, Miguel Martin, Frankie A. Holmes, Bent Ejlertsen, Suzette Delaloge, Beverly Moy, Hiroji Iwata, Gunter von Minckwitz, Janine Mansi, Carlos H. Barrios, Mic...> ;Breast Cancer Research. 2019 Mar 11
27 citations
Pretreatment Psychoneurological Symptoms and Their Association With Longitudinal Cognitive Function and Quality of Life in Older Breast Cancer Survivors
Danielle Tometich, Brent J. Small, Judith E. Carroll, Wanting Zhai, George Luta, Xingtao Zhou, Lindsay C. Kobayashi, Tim A. Ahles, Andrew J. Saykin, Jonathan D Clapp, ...> ;Journal of Pain and Symptom Management. 2019 Mar 1
Join now to see all

Lectures

Tailored Therapy for Early-Stage HER2+ Breast Cancer
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

The Ongoing Challenge of Pandemic Fatigue Is Hitting People HardJanuary 13th, 2021
Cardiotoxicity in Cancer Tx: LVEF Less Than 55% Is PredictiveJune 17th, 2020
11 Symptoms of Breast Cancer in Women That Aren’t LumpsSeptember 24th, 2019
Join now to see all